The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
about
Non-hormonal interventions for hot flushes in women with a history of breast cancerOptimal delivery of male breast cancer follow-up care: improving outcomesThromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data.Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy.Venous gangrene and cancer: a cool look at a burning issue.Venous thromboembolism in cancer patients.SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyClinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer: A Retrospective Cohort Analysis.Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient.Venous thromboembolic disease and cancerManagement of venous thromboembolism in patients with cancer: role of dalteparin.Venous thromboembolism prevention in cancer patients: the search for common antecedents.Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.The prothrombotic activity of cancer cells in the circulationRisk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.A review of the use of exemestane in early breast cancer.The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment.Treatment of thromboembolism in cancer patients.Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients.Primary venous thromboembolism prophylaxis in ambulatory cancer patients.Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.Venous thromboembolism in cancer patients: risk assessment, prevention and management.Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.Heparanase procoagulant activity is elevated in women using oral contraceptives.Prognostic value of routine laboratory variables in prediction of breast cancer recurrenceTamoxifen Use Correlates with Increased Risk of the First Episode of Ischemic Cerebrovascular Disease in Older Women with Breast Cancer: A Case-Control Study in Taiwan.Guideline on aspects of cancer-related venous thrombosis.Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study.The incidence and predictors of thromboembolic events in patients with lung cancer
P2860
Q24235391-D60DA953-14E6-476A-A327-3513CA0C2D41Q26773195-304E5650-C1C1-45AD-8E28-57957219DF56Q26995284-7758FC29-BD2C-4DDD-9A91-DC5A4B0273B0Q31024426-55F7C678-F4A3-4D28-87CE-DE54E6DDF296Q33239343-918EA344-FDC1-4335-9583-33181C04F96DQ33374683-59746709-EA4D-4172-B4AD-424280686E6CQ33419213-E3AD2AEF-759E-4A67-9C42-F29E7F13217AQ34307873-D458EBF0-6D7F-44E7-B603-03AF218CEBFEQ34688195-A280D465-2F05-447D-A448-A8057729B7B6Q35056229-1357BD54-E324-4E08-91D7-FBD5111FFBC8Q35058455-728205E4-74D5-4B3C-A9FA-53056A861941Q36195386-1DDE97F3-238B-4765-8297-E1E6BB4E9C50Q36265574-AC03A4AA-1B29-446F-9D69-72483AF2B155Q36636027-08336E45-81B7-4D4B-B8FC-2A36B9CB1570Q36812767-6498CB35-B649-4F56-920D-31B7809DDCA0Q36916924-AD4DAA4B-BB3A-4358-A0AF-41B2D2E657CCQ37023306-82F92F6A-7C06-43CC-9463-199DDA2FF4BDQ37088087-DE47DE6B-5ACB-430A-91D3-689B724E6643Q37142210-E508C8D7-4B81-4DA5-BC48-24C000BAE2DAQ37230265-BBAB3248-ED19-4FCF-9776-E75903A246B5Q37374557-207253E8-69B4-4D5B-9E38-8456FEC74CABQ37773994-07FAA33E-250B-4EBC-8870-A4F882308425Q37848581-7141B729-51D6-41C5-8DA7-B104B6CE6AC5Q38079522-17419043-51FB-46D0-AB71-7CD6925F2D4EQ38086121-D2C0C1E3-F2F9-4F10-802F-4B2CBCEC79D1Q38751462-2B78E3A9-5B55-447D-BED7-B0B5E80FE771Q38968554-CBEDB409-F78D-4657-BBCB-296E4EC6EFBDQ39135103-32CF7DE1-833A-491D-8EE9-B34FEA7A1D3CQ41421740-D54ADD43-6979-4682-BA4E-B1204A5D4409Q44328480-4B98957B-0453-49CB-8260-2788BA1CC87BQ45877193-364B9365-ED7C-4DEA-A0CA-A24435DE8280Q48661559-32920291-AD12-4B05-BC84-FB81E583898AQ59074701-D8AC756B-A562-4D08-AD72-27CE26B58A12
P2860
The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The risk of venous thromboembo ...... arcinoma: a systematic review.
@ast
The risk of venous thromboembo ...... arcinoma: a systematic review.
@en
type
label
The risk of venous thromboembo ...... arcinoma: a systematic review.
@ast
The risk of venous thromboembo ...... arcinoma: a systematic review.
@en
prefLabel
The risk of venous thromboembo ...... arcinoma: a systematic review.
@ast
The risk of venous thromboembo ...... arcinoma: a systematic review.
@en
P356
P1433
P1476
The risk of venous thromboembo ...... arcinoma: a systematic review.
@en
P2093
Marcelo P V Gomes
Steven R Deitcher
P304
P356
10.1002/CNCR.20347
P407
P577
2004-08-01T00:00:00Z